Cellectis (CLLS) Operating Margin (2015 - 2026)
Cellectis (CLLS) posted quarterly Operating Margin of 435.64% for Q1 2026, down 30257.0% year-over-year from N/an in Q1 2025, and down 219.25% quarter-over-quarter from 136.46% in Q4 2025.
Analysis
Cellectis (CLLS) Operating Margin (2015 - 2026) Analysis & Trends
Cellectis' Operating Margin history runs 12 years deep, the most recent figure standing at 435.64% for Q1 2026.
- In Q1 2026, Operating Margin fell 30257.0% year-over-year to 435.64%; the TTM figure through Mar 2026 stood at 62.6% (up 3287.0% YoY), while the FY2025 annual figure was 81.64%, up 3937.0% from the prior year.
- Operating Margin for Q1 2026 stood at 435.64%, down from 136.46% in the prior quarter.
- The five-year high for Operating Margin was 22.86% in Q3 2025, with the low at 16856.83% in Q1 2023.
- The 5-year median for Operating Margin is 339.17% (2023), against an average of 3814.5%.
- The sharpest annual moves came in 2022 and 2024: Operating Margin sank 1512056 bps in 2022, then surged 1639539 bps in 2024.
- Cellectis' Operating Margin stood at 35.32% in 2022, then slumped by 860 bps to 339.17% in 2023, then soared by 85 bps to 52.28% in 2024, then sank by 161 bps to 136.46% in 2025, then tumbled by 219 bps to 435.64% in 2026.
- Business Quant data shows CLLS's Operating Margin at 435.64% in Q1 2026, 136.46% in Q4 2025, and 22.86% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -449.82% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -449.82% |
| Mar 31, 2026 | -435.64% |
| Dec 31, 2025 | -136.46% |
| Sep 30, 2025 | 22.86% |
| Jun 30, 2025 | -57.32% |
| Mar 31, 2025 | -133.07% |
| Dec 31, 2024 | 95.26% |
| Sep 30, 2024 | -66.48% |
| Jun 30, 2024 | -213.51% |
| Mar 31, 2024 | -461.44% |
| Dec 31, 2023 | -14,768.55% |
| Sep 30, 2023 | -13,336.13% |
| Jun 30, 2023 | -13,270.22% |
| Mar 31, 2023 | -20,023.74% |
| Dec 31, 2022 | -35.32% |
| Sep 30, 2022 | -15,630.29% |
| Jun 30, 2022 | -2,089.75% |
| Mar 31, 2022 | -1,755.44% |
| Dec 31, 2021 | -239.33% |
| Sep 30, 2021 | -509.72% |